TG Therapeutics
TGTX
116 hedge funds and large institutions have $434M invested in TG Therapeutics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 13 closing their positions.
358% more call options, than puts
Call options by funds: $17M | Put options by funds: $3.71M
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
12% more capital invested
Capital invested by funds: $387M → $434M (+$47.5M)
3% more funds holding
Funds holding: 113 → 116 (+3)
0.6% more ownership
Funds ownership: 54.7% → 55.31% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$7.56M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.88M |
| 4 |
BlackRock
New York
|
+$6.55M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Agricole
Montrouge Cedex,
France
|
-$10.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.96M |
| 3 |
BM
Bridger Management
New York
|
-$4.45M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.38M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.07M |
TGTX Hedge Fund Activity: Q2 2019 in Review
116 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2019, worth a combined $434M — up 12% from $387M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TGTX positions and 13 closed out — a net gain of 5 holders — while 44 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $14.8M. The largest seller was Credit Agricole, exiting entirely with an estimated $10.5M sold.
- 116 institutional investors held TG Therapeutics (TGTX) as of Q2 2019, up from 113 in Q1 2019.
- Funds reported $434M of TG Therapeutics stock for Q2 2019, up 12% quarter-over-quarter.
- 18 funds opened new TG Therapeutics positions in Q2 2019 and 13 closed out, a net change of +5 holders.
- The largest TG Therapeutics buyer in Q2 2019 was State Street, an estimated $14.8M added.
- The largest TG Therapeutics seller in Q2 2019 was Credit Agricole, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2019.